FDA opens up access to experimental meds

Seriously ill patients with no remaining therapeutic options will be given access to experimental meds under new rules released by the FDA. In the face of developers' worries that open access to experimental drugs could scuttle the clinical trial process, giving patients less reason to volunteer for a study, the agency has required that the developer and the FDA have to jointly agree on preclinical use of a drug. Patients can be charged for the cost of manufacturing and administering the drug. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.